ALLERGAN USA, INC. for ALLERGAN USA, INC.
What was lobbied
8 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Strategic market-based trade policies to promote access and proven intellectual property standards that drive innovation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENT J FISK | — |
| ROBERT W. LIVELY | — |
Copyright/Patent/Trademark CPT
Patent Reform Proposals; Patent Settlement Proposals. Intellectual property protections for novel therapies to treat crucial medical needs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENT J FISK | — |
| ROBERT W. LIVELY | — |
Budget/Appropriations BUD
Medicare and Medicaid Provisions reimbursement. Aligning reimbursements to allow patient access to critical medical treatments. Agriculture, Rural Development, Food and Drug Administration Appropriations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENT J FISK | — |
| ROBERT W. LIVELY | — |
Pharmacy PHA
Ensuring the safety of the drug supply chain to keep Americans safe. Drug Labeling Drug Importation/Counterfeit drugs Drug Compounding Track and Trace
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENT J FISK | — |
| ROBERT W. LIVELY | — |
Medical/Disease Research/Clinical Labs MED
Drug safety and efficacy;bioequivalence issues. Upholding the gold standard of safety and efficacy to protect patients.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENT J FISK | — |
| ROBERT W. LIVELY | — |
Health Issues HCR
Access to appropriate mental health care treatments across the U.S. H.R. 2646 - Helping Families in Mental Health Crisis Act of 2016; S. 2680 Mental Health Reform Act of 2016.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENT J FISK | — |
| ROBERT W. LIVELY | — |
Taxation/Internal Revenue Code TAX
Tax Policy including changes to corporate tax structure. Tax codes that ensure investment in research & development of novel treatments for patients.
Foreign entity interest: Allergan plc, as the indirect parent of Allergan USA, Inc., has an interest to the extent the tax code affects foreign operations.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENT J FISK | — |
| ROBERT W. LIVELY | — |
Medicare/Medicaid MMM
Medicare Improvement for Patients and Providers Act of 2008 (P.L. 110-275) Reimbursement policy and coverage issues. Improving coverage and reimbursement for treatments to enhance the lives of patients. Reimbursements to help those affected by antibiotic resistant diseases.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRENT J FISK | — |
| ROBERT W. LIVELY | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.